Hecla Mining Company Common Stock vs TG Therapeutics Inc — how do they compare? Hecla Mining Company Common Stock trades at $17.31 (market cap $11.24B), while TG Therapeutics Inc trades at $55.27 (market cap $8.16B). The key difference: Hecla Mining Company Common Stock is the larger of the two by market cap, and Hecla Mining Company Common Stock pays a 0.09% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hecla Mining Company Common Stock for 0 Days and TG Therapeutics Inc for 15 Days on average.
| HL | TGTX | |
|---|---|---|
Market Cap | $11.24B | $8.16B |
Volume | 37,227,749 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $31.81 | $59.06 |
52-Week Low | $11.97 | $26.94 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $10.77B | $8.37B |
Dividend Yield | 0.09% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Hecla Mining is a precious metals producer focused on silver and gold. It operates mines in the United States and Canada.
Read more on HL →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →